Viventia Biotechnologies Inc. (“Viventia"), is a privately-held biopharmaceutical company developing and advancing next generation human monoclonal antibodies (mAbs) in oncology.  Viventia’s lead mAb product, Vicinium™, has completed a Phase II study and is scheduled to start Phase III clinical trials for the treatment of non-muscle invasive bladder cancer.

Viventia is building a product pipeline using its innovative monoclonal antibody (mAb) discovery platform, IDAP (Immune Driven Antibody Platform), a collection of technologies designed to validate a differentiated portfolio of new antibody products with the potential to identify new oncology drug targets.

Other products include VB6-845, a clinical stage mAb product for the systemic treatment of various EpCAM-positive solid tumors that has undergone preliminary investigation in a phase I clinical trial and is continuing to be developed for further phase I testing.

Viventia is headquartered in Mississauga, Canada and its research and cGMP antibody production facility is located in Winnipeg, Canada

Core Assets